Biotech Values

[JohnWayne]

In addition to likely primary analysis at 25% cutoff, trial is likely large enough for hierarchical analysis at other cutoffs.

IIRC, AZ's 25% cutoff is approx same prevalence as MRK's 50% cutoff, will be interesting to see how efficacy of CTLA4 combo compares to monotherapy in PD-L1 "strong positive"